PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tadalafil - Erectile dysfunction combination therapy
PAD Profile : Tadalafil - Erectile dysfunction combination therapy
Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence
Brand Names Include :
Cialis
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Policy Statement
Erectile dysfunction oral and non oral combination treatments - Policy statement PCN 24-2012 - Jun 2
01 June 2025
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
27 June 2012
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Use of both oral and non-oral combination treatments for erectile dysfunction in patients who had not responded or had a sub-optimal response to monotherapy was considered.The network members concurred that based on the limited available evidence, noting the feedback from clinicians, that combination treatments should not be supported and a BLACK status should be given on the PAD.Please see policy statement from June 2012
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction